98 related articles for article (PubMed ID: 36074149)
1. Preclinical development of novel PD-L1 tracers and first-in-human study of [
Zhang Y; Cao M; Wu Y; Malih S; Xu D; Yang E; Younis MH; Lin W; Zhao H; Wang C; Liu Q; Engle JW; Rasaee MJ; Guan Y; Huang G; Liu J; Cai W; Xie F; Wei W
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580333
[TBL] [Abstract][Full Text] [Related]
2. Development and
Bamminger K; Pichler V; Vraka C; Limberger T; Moneva B; Pallitsch K; Lieder B; Zacher AS; Ponti S; Benčurová K; Yang J; Högler S; Kodajova P; Kenner L; Hacker M; Wadsak W
J Med Chem; 2024 Mar; 67(5):4036-4062. PubMed ID: 38442487
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 as a Urine Biomarker in Renal Cell Carcinoma-A Case Series and Proof-of-Concept Study.
Reimold P; Tosev G; Kaczorowski A; Friedhoff J; Schwab C; Schütz V; Görtz M; Panzer N; Heller M; Aksoy C; Himmelsbach R; Walle T; Zschäbitz S; Jäger D; Duensing A; Stenzinger A; Hohenfellner M; Duensing S
Diagnostics (Basel); 2024 Mar; 14(7):. PubMed ID: 38611655
[TBL] [Abstract][Full Text] [Related]
4. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma.
Weinstock M; McDermott D
Ther Adv Urol; 2015 Dec; 7(6):365-77. PubMed ID: 26622321
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET/CT imaging of clear cell renal cell carcinoma with [
Wu Q; Wu Y; Zhang Y; Guan Y; Huang G; Xie F; Liu J; Zhai W; Wei W
Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38480552
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study.
Hegi-Johnson F; Rudd SE; Wichmann CW; Akhurst T; Roselt P; Sursock S; Trinh J; John T; Devereux L; Donnelly PS; Hicks RJ; Scott AM; Steinfort D; Fox S; Blyth B; Parakh S; Hanna GG; Callahan J; Burbury K; MacManus M
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):675-682. PubMed ID: 37406824
[No Abstract] [Full Text] [Related]
7. [
Massicano AVF; Song PN; Mansur A; White SL; Sorace AG; Lapi SE
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345044
[TBL] [Abstract][Full Text] [Related]
8. Click Here for Better Chemistry.
Zeglis BM; Lewis JS
N Engl J Med; 2022 Dec; 387(24):2291-2293. PubMed ID: 36449446
[No Abstract] [Full Text] [Related]
9. Radiopharmaceuticals as Novel Immune System Tracers.
Ridge NA; Rajkumar-Calkins A; Dudzinski SO; Kirschner AN; Newman NB
Adv Radiat Oncol; 2022; 7(5):100936. PubMed ID: 36148374
[TBL] [Abstract][Full Text] [Related]
10. PET Imaging of Peptide Probe Al[
Zhang Y; Wang Y; Chen Y; Ding X; Wang S; Liu W; Hu M; Liu Z
Mol Pharm; 2024 Mar; 21(3):1515-1525. PubMed ID: 38291578
[TBL] [Abstract][Full Text] [Related]
11. Inspired by novel radiopharmaceuticals: Rush hour of nuclear medicine.
Liu Y; Ren YN; Cui Y; Liu S; Yang Z; Zhu H; Li N
Chin J Cancer Res; 2023 Oct; 35(5):470-482. PubMed ID: 37969954
[TBL] [Abstract][Full Text] [Related]
12. Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy.
Li A; Luo L; Du W; Yu Z; He L; Fu S; Wang Y; Zhou Y; Yang C; Yang Y; Fang W; Zhang L; Hong S
NPJ Precis Oncol; 2023 Sep; 7(1):87. PubMed ID: 37696887
[TBL] [Abstract][Full Text] [Related]
13. Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy.
Mulgaonkar A; Udayakumar D; Yang Y; Harris S; Öz OK; Ramakrishnan Geethakumari P; Sun X
Front Med (Lausanne); 2023; 10():1199146. PubMed ID: 37441689
[TBL] [Abstract][Full Text] [Related]
14. Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Radiation Therapy Treatment Planning: A Review of PET Imaging Tracers and Methods to Incorporate PET/CT.
Trotter J; Pantel AR; Teo BK; Escorcia FE; Li T; Pryma DA; Taunk NK
Adv Radiat Oncol; 2023; 8(5):101212. PubMed ID: 37197709
[TBL] [Abstract][Full Text] [Related]
15. Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis.
Trencsényi G; Képes Z
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108559
[TBL] [Abstract][Full Text] [Related]
16. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.
Mulgaonkar A; Elias R; Woolford L; Guan B; Nham K; Kapur P; Christie A; Tcheuyap VT; Singla N; Bowman IA; Stevens C; Hao G; Brugarolas J; Sun X
Clin Cancer Res; 2022 Nov; 28(22):4907-4916. PubMed ID: 36074149
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 detection using
Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model.
Bansal A; Pandey MK; Barham W; Liu X; Harrington SM; Lucien F; Dong H; Park SS; DeGrado TR
Nucl Med Biol; 2021; 100-101():4-11. PubMed ID: 34119742
[TBL] [Abstract][Full Text] [Related]
19. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
